| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Collaboration revenue | 8,659 | 8,513 | 4,127 | 11,514 |
| Research and development | 25,283 | 22,507 | 25,142 | 26,256 |
| General and administrative | 6,215 | 6,993 | 6,805 | 7,641 |
| Total operating expenses | 31,498 | 29,500 | 31,947 | 33,897 |
| Loss from operations | -22,839 | -20,987 | -27,820 | -22,383 |
| Interest income | 2,214 | 2,485 | 2,887 | 3,616 |
| Change in fair value of long-term investments | 0 | 1,292 | - | 2,055 |
| Other expense, net | -2 | -70 | -8 | -57 |
| Total other income, net | 2,212 | 1,123 | 2,879 | 1,504 |
| Net loss before provision for income taxes | -20,627 | -19,864 | -24,941 | -20,879 |
| Benefit from income taxes | -234 | 44 | 98 | -2,106 |
| Net loss | -20,393 | -19,908 | -25,039 | -18,773 |
| Unrealized gain (loss) on available-for-sale marketable securities | -1 | -249 | -88 | 1,904 |
| Comprehensive loss | -20,394 | -20,157 | -25,127 | -16,869 |
| Earnings per share, basic, total | -0.55 | -0.54 | -0.68 | -0.51 |
| Earnings per share, diluted, total | -0.55 | -0.54 | -0.68 | -0.51 |
| Weighted average number of shares outstanding, basic, total | 37,349,449 | 37,156,979 | 37,019,027 | 36,766,309 |
| Weighted average number of shares outstanding, diluted, total | 37,349,449 | 37,156,979 | 37,019,027 | 36,766,309 |
Metagenomi, Inc. (MGX)
Metagenomi, Inc. (MGX)